Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Phase 1

Completed

Conditions: Advanced BRAF Mutant Cancers

Interventions: Drug: Binimetinib
Drug: Encorafenib

First Posted Date: 2019-02-18

Last Posted Date: 2024-10-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03843775

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack, New York, United States

and more 1 locations

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Completed

Conditions: Cutaneous Melanoma

Interventions: Behavioral: Demographics Questionnaire
Behavioral: Adjuvant Treatment Beliefs Scale10
Behavioral: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
Behavioral: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
Behavioral: Decisional Regret14
Behavioral: Clinician Preference for Treatment

First Posted Date: 2019-02-18

Last Posted Date: 2023-01-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 38

Registration Number: NCT03843593

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Early Phase 1

Active, not recruiting

Conditions: Solid Tumors
Identified by NGS, PCR or IHC

Interventions: Drug: Pembrolizumab

First Posted Date: 2019-02-06

Last Posted Date: 2024-04-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03832569

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)

Interventions: Drug: Zanubrutinib
Drug: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2019-01-31

Last Posted Date: 2024-11-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 230

Registration Number: NCT03824483

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Massachusetts General Hospital (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment

Active, not recruiting

Conditions: Fertility Preservation
Breast Cancer

Interventions: Behavioral: web-based questionnaire

First Posted Date: 2019-01-28

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 209

Registration Number: NCT03817814

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

Early Phase 1

Active, not recruiting

Conditions: Solid Tumors
Preoperative Aerobic Training

Interventions: Behavioral: treadmill walking Dose-Finding / Escalation
Behavioral: treadmill walking (Proof-of-Concept)

First Posted Date: 2019-01-23

Last Posted Date: 2024-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT03813615

Locations: 🇺🇸
University of California, Los Angeles (Data Analysis only), Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 5 locations

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: Dacomitinib
Drug: Osimertinib

First Posted Date: 2019-01-22

Last Posted Date: 2024-02-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT03810807

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2019-01-18

Last Posted Date: 2024-04-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT03810105

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 5 locations

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer
Metastatic Breast Cancer
Non Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Carcinoma

Interventions: Drug: Systemic Therapy/Standard of Care
Radiation: Stereotactic Body Radiotherapy/SBRT

First Posted Date: 2019-01-17

Last Posted Date: 2024-10-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 145

Registration Number: NCT03808337

Locations: 🇺🇸
Natera, Inc. (Data and Specimen Analysis Only), San Carlos, California, United States
🇺🇸
WCHN Norwalk Hospital - Data Collection, Norwalk, Connecticut, United States
🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States

and more 9 locations

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Rocuronium 0.3mg/kg/hr
Drug: Rocuronium 1.5mg/kg/hr

First Posted Date: 2019-01-17

Last Posted Date: 2024-10-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 139

Registration Number: NCT03808077

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy